Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data

Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become t | Less than a month after Ionis scored an FDA expansion for Tryngolza to become the first drug to specifically treat severe hypertriglyceridemia, Arrowhead has countered with head-turning data from two phase 3 trials that could set the company up for a matching nod.